FindTrial
Sign In

The peptide spectrum analysis in elderly patients with Alzheimer's disease and patients with type 2 diabetes mellitus

Drug intervention and its mechanism of early Alzheimer's disease

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR1800014451
Enrollment
Unknown
Registered
2018-01-15
Start date
2015-01-01
Completion date
Unknown
Last updated
2018-01-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Alzheimer's disease,type 2 diabetes mellitus

Interventions

Control group versus T2DM group versus AD group:Nil

Sponsors

Qingdao Municipal Hospital of Shandong Province
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Control group: Fasting blood glucose is 3.9-6.1mmol/L, 2hPG<6.1mmol/L, no cognitive dysfunction; T2DM group: meet the 1999 diagnostic standard of WHO diabetes expert committee, no diabetes complication; AD group: IWG2014 diagnostic standard, no diabetes.

Exclusion criteria

Exclusion criteria: Hypertension, coronary heart disease, stroke, cerebrovascular disease, head injury, Parkinson syndrome.

Design outcomes

Primary

MeasureTime frame
the level of protein in urine;the level of protein in blood;—

Countries

China

Contacts

Public ContactSong Dalin

Qingdao Municipal Hospital of Shandong Province

songdalin@medmail.com.cn+86 18561728001

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026